Advertisement
UK markets close in 44 minutes

  • FTSE 100

    8,036.58
    +12.71 (+0.16%)
     

  • FTSE 250

    19,753.44
    +154.05 (+0.79%)
     

  • AIM

    754.73
    +5.55 (+0.74%)
     

  • GBP/EUR

    1.1631
    +0.0043 (+0.37%)
     

  • GBP/USD

    1.2452
    +0.0102 (+0.83%)
     

  • Bitcoin GBP

    53,620.49
    +365.47 (+0.69%)
     

  • CMC Crypto 200

    1,437.84
    +23.08 (+1.63%)
     

  • S&P 500

    5,059.49
    +48.89 (+0.98%)
     

  • DOW

    38,443.91
    +203.93 (+0.53%)
     

  • CRUDE OIL

    82.07
    +0.17 (+0.21%)
     

  • GOLD FUTURES

    2,334.80
    -11.60 (-0.49%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,095.56
    +234.76 (+1.31%)
     

  • CAC 40

    8,093.27
    +52.91 (+0.66%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act

BioPorto A/S
·1-min read

April 8, 2021
Announcement no. 6

Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act

The Company’s share capital has been increased by normally DKK 1,172,500, corresponding to 1,172,500 new shares, as a result of exercise of warrants issued under the Company’s incentive warrant program. Total proceeds from the capital increase amount to approximately DKK 4.4 million.
The new shares have rights to dividends and other rights in the Company as from 8 April 2021. The new shares will be listed on Nasdaq Copenhagen, expectedly with first day of trading on 12 April 2021.

After the share capital increase, the Company’s share capital amounts to nominally DKK 267,754,404 divided into 267,754,404 shares each carrying 1 voting right, corresponding to a total of 267,754,404 voting rights, cf. section 32 of the Danish Capital Markets Act.

ADVERTISEMENT

Amended Articles of Association reflecting the above are available on the Company’s website.

For further information, please contact:

Ole Larsen, CFO

Telephone +45 4529 0000, e-mail: investor@bioporto.com

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment